EVEROLIMUS WITH REDUCED TACROLIMUS MAINTAINS EFFICACY FOLLOWING LIVING-DONOR LIVER TRANSPLANTATION (LDLT): 12-MONTH RESULTS FROM AN INTERNATIONAL RANDOMIZED TRIAL (NCT01888432)

被引：0
|
作者：
Braun, F. [1 ]
Settmacher, U. [2 ]
Lopez, P. M. [3 ]
Kochuparampil, J. [3 ]
Lieb, S. [4 ]
机构：
[1] Univ Klinikum Schleswig Holstein, Kiel, Germany
[2] Univ Klinikum Jena, Klin Allgemein Viszeral & Gefasschirurg, Jena, Germany
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharma GmbH, TA Transplantat & Rheumatol, Nurnberg, Germany
来源：
TRANSPLANT INTERNATIONAL | 2017年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
PV51
引用
收藏
页码：26 / 26
页数：1
相关论文
共 30 条
  • [21] Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial
    Hesselink, D.
    Shuker, N.
    Osinga, J.
    Clahsen-van Groningen, M.
    Damman, J.
    Baan, C.
    van de Wetering, J.
    Rowshani, A.
    Kal-van Gestel, J.
    Weimar, W.
    van Gelder, T.
    Bouamar, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 732 - 733
  • [22] EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED EXPOSURE TACROLIMUS OR CYCLOSPORINE IN PEDIATRIC LIVER TRANSPLANTATION-24-MONTH RESULTS FROM H2305 STUDY.
    Ganschow, R.
    Ericzon, B. -G.
    Dhawan, A.
    Sharif, K.
    Martzloff, E. -D.
    Rauer, B.
    Ng, J.
    Lopez, P. M.
    PEDIATRIC TRANSPLANTATION, 2017, 21 : 13 - 13
  • [23] Efficacy and safety of everolimus in combination with reduced tacrolimus in de novo liver transplant recipients: 36-month results from the randomized H2304 study
    Saliba, Faouzi
    Kaiser, Gernot M.
    De Carlis, Luciano
    Metselaar, Herold J.
    De Simone, Paolo
    Duvoux, Christophe
    Nevens, Frederik
    Fischer, Lutz
    Fung, John J.
    Dong, Gaohong
    Rauer, Barbara
    Junge, Guido
    HEPATOLOGY, 2013, 58 (06) : 1383A - 1383A
  • [24] EFFICACY AND SAFETY OF EVEROLIMUS IN COMBINATION WITH REDUCED TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS: 36-MONTH RESULTS FROM THE RANDOMIZED H2304 STUDY
    Saliba, F.
    Duvoux, C.
    Durand, F.
    Neau-Cransac, M.
    Hardwigsen, J.
    Pageaux, G.
    Di Giambattista, F.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 18 - 18
  • [25] Effect of everolimus plus reduced-dose tacrolimus in de novo living-donor liver transplantation recipients on recurrence of HCC: 24 months subgroup analysis from the H2307 study
    Jeng, L. -B.
    Lee, S. -G.
    Soin, A. S.
    Lee, W. -C.
    Suh, K. -S.
    Joo, D. J.
    Uemoto, S.
    Meier, M.
    Kochuparampil, J.
    Sips, C.
    Kaneko, S.
    Levy, G.
    TRANSPLANTATION, 2018, 102 : 300 - 301
  • [26] EVEROLIMUS PLUS REDUCED TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS ACHIEVES COMPARABLE OVERALL EFFICACY WITH FEWER BIOPSY-PROVEN ACUTE REJECTIONS VERSUS STANDARD TACROLIMUS: 24-MONTH RESULTS OF A RANDOMIZED TRIAL
    Fung, J.
    Fischer, L.
    Kaiser, G.
    Jonas, S.
    Heise, M.
    Schemmer, P.
    Pascher, A.
    Schlitt, H.
    Paulus, E.
    Mertens, M.
    Nevens, F.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 4 - 4
  • [27] Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial
    Dantal, Jacques
    Berthoux, Francois
    Moal, Marie-Christine
    Rostaing, Lionel
    Legendre, Christophe
    Genin, Robert
    Toupance, Olivier
    Moulin, Bruno
    Merville, Pierre
    Rerolle, Jean-Philippe
    Bayle, Francois
    Westeel, Pierre Francois
    Glotz, Denis
    Kossari, Niloufar
    Lefrancois, Nicole
    Charpentier, Bernard
    Quere, Stephane
    Di Giambattista, Fabienne
    Cassuto, Elisabeth
    TRANSPLANT INTERNATIONAL, 2010, 23 (11) : 1084 - 1093
  • [28] Everolimus with reduced-exposure cyclosporine versus MMF and standard-exposure cyclosporine in de novo cardiac transplant recipients: 12-month results from a multicenter, Randomized trial
    Arizon, Jose
    Lehmkuhl, Hans
    Livi, Ugolino
    Vigano, Mario
    Branzi, Angelo
    Almenar, Luis
    Gerosa, Gino
    Musumeci, Francesco
    Vamous, Shaida
    Maccherini, Massimo
    Hexham, Mark
    Mange, Kevin C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 : 211 - 211
  • [29] LINEAR GROWTH AND SEXUAL MATURATION WITH EVEROLIMUS PLUS REDUCED CALCINEURIN INHIBITOR-BASED REGIMEN IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS: 12-MONTH RESULTS FROM CRAD001H2305-STUDY (NCT01598987)
    Briem-Richter, A.
    Grabhorn, E.
    Brinkert, F.
    Yap, J.
    Rasmussen, A.
    Martzloff, E. D.
    Rauer, B.
    Ng, J.
    Lopez, P. M.
    TRANSPLANT INTERNATIONAL, 2017, 30 : 35 - 35
  • [30] Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial (vol 23, pg 1084, 2010)
    Dantal, J.
    Berthoux, F.
    Moal, M-C
    Rostaing, L.
    Legendre, C.
    Genin, R.
    Toupance, O.
    Moulin, B.
    Merville, P.
    Rerolle, J-P
    Bayle, F.
    Westeel, P. F.
    Glotz, D.
    Kossari, N.
    Lefrancois, N.
    Charpentier, B.
    Quere, S.
    Di Giambattista, F.
    Cassuto, E.
    TRANSPLANT INTERNATIONAL, 2012, 25 (01) : 138 - 138
123